Jain Global’s Xeris Biopharma Holdings XERS Stock Holding History

Jain Global’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,114	Closed	-$87.2K	–	1703
2025 Q4	$87.2K	Buy	+11,114	New	+$87.5K	﹤0.01%	1120

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jain Global's XERS Position: Q1 2026 in Review

Jain Global sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 11,114 shares — an estimated $87.2K sold.

Jain Global first reported a position in XERS in Q4 2025 and held it in 1 quarter. The position peaked at $87.2K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Jain Global reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
Jain Global sold 11,114 Xeris Biopharma Holdings shares in Q1 2026, an estimated $87.2K.
Jain Global first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 1 quarter.
Jain Global's Xeris Biopharma Holdings position peaked at $87.2K in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.